Aktuelle Entwicklungen in Diagnostik und Therapie von Kollagenosen

systemischer Lupus erythematodes - progressive systemische Sklerose - Morbus Sjörgen - Dermatomyositis

systemic lupus erythematodes - scleroderma - sjögren's syndrome - dermatomyositis

Literatur

• 1 Appel G B, Contreras G, Dooley M A. et al . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.  J Am Soc Nephrol. 2009;  20 1103-1112
• 2 Brueckner C S, Becker M O, Kroencke T. et al . Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.  Ann Rheum Dis. 2010;  69 1475-1478
• 3 Dass S, Bowman S J, Vital E M. et al . Reduction of fatigue in sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.  Ann Rheum Dis. 2008;  67 1541-1544
• 4 Derk C T, Grace E, Shenin M. et al . A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.  Rheumatology. 2009;  48 1595-1599
• 5 Fernández R, Rubio C, Cano S. et al . Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.  Clin Exp Rheumatol. 2009;  17 1009-1016
• 6 Houssiau F A, D’Cruz D, Sangle S. et al . Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial.  Ann Rheum Dis. 2010;  69 2083-2089
• 7 Izmirly P M, Kim M Y, Llanos C. et al . Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestation of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.  Ann Rheum Dis. 2010;  69 1827-1830
• 8 Jung H, Bobba R, Su J. et al . The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematodes.  Arthritis Rheum. 2010;  62 863-868
• 9 Liang J, Zhang H, Hua B. et al . Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study.  Ann Rheum Dis. 2010;  69 1423-1429
• 10 Merrill J T, Neuwelt C M, Wallace D J. et al . Efficacy and safety of rituximab in Moderately-to-severely active lupus erythematosus.  Arthritis Rheumat. 2010;  62 222-233
• 11 Rupprecht K, Schmidt C h, Raspé A. et al . Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers.  J Clin Pharmacol. 2009;  49 1196-1201
• 12 Sabnani I, Zucker M J, Rosenstein E D. et al . A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.  Rheumatology. 2009;  48 49-52
• 13 Shinjo S K, Bonfa E, Wojdyla D. et al . Antimalarial treatment may have a time-dependent effect on lupus survival.  Arthritis Rheum. 2010;  62 855-862
• 14 Wallace D J, Stohl W, Furie R A. et al . A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of blimumab in patients with active systemic lupus erythematosus.  Arthritis Rheum. 2009;  61 1168-1178
• 15 Zahr N, Arnaud L, Marquet P. et al . Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.  Arthritis Rheum. 2010;  62 2047-2054